Boule Diagnostics AB announced that it has received funding from Keel Capital Ab
September 06, 2022
Share
Boule Diagnostics AB (publ) announced a private placement of shares on September 7, 2022. The transaction included participation from returning investor, Keel Capital Ab which has increased its ownership to over 5 percent of the shares through this round.
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Companyâs product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Companyâs primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
BOULE DIAGNOSTICS AB 
